FIELD: medicine.
SUBSTANCE: group of inventions refers to the long-term use of an parenteral formulation for producing a medicinal preparation for treating a HIV-infected individual with the above preparation applicable for subcutaneous or intramuscular injections and consists of brecanavir, or its salt in the form of an aqueous micro- or nanoparticle suspension containing Polysorbate 20, and is administered at regular intervals from 6 to 12 months, and to the above pharmaceutical composition.
EFFECT: reducing the number of injections of the composition (preparation) in the absence of the additional agent ritonavir.
7 cl, 4 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| LYOPHILIZED DRUG NANOSUSPENSIONS | 2012 |
|
RU2643062C2 |
| CRYSTALLINE FORM OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE | 2008 |
|
RU2498979C2 |
| PHARMACEUTICAL NANOSUSPENSION FOR TREATMENT OF HIV INFECTION | 2017 |
|
RU2665383C1 |
| ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
| METHOD OF TREATING NEUROPATHIC PAIN AND ASSOCIATED WITH IT SYNDROMES | 2005 |
|
RU2433825C2 |
| SCHEMES FOR TREATMENT OF HIV-INFECTIONS AND AIDS | 2018 |
|
RU2784810C2 |
| HYBRID POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES | 1999 |
|
RU2236865C2 |
| DIESTER NALMEFENE PRODRUGS | 2009 |
|
RU2495041C2 |
| PHARMACEUTICAL COMPOSITION (VARIANTS), PREPARATION AND METHOD OF TREATMENT OF STATE SUSCEPTIBLE TO EFFECT OF LHRH ANALOGUE, SYRINGE | 1997 |
|
RU2202371C2 |
| METHOD FOR TREATMENT OF PROSTATE GLAND DISEASES BASED ON LOCAL DELIVERY OF ACTIVE MATERIALS | 2006 |
|
RU2404747C2 |
